论文部分内容阅读
目的:分析雾化吸入重组人干扰素α1b治疗小儿急性毛细支气管炎的安全性和疗效。方法:数字随机抽取我院2015年1月至2016年1月我院收治的40例急性毛细支气管炎患儿,分为两组,给予对照组常规对症治疗,在对照组基础上,给予观察组雾化吸入重组人干扰素α1b治疗,对比两组临床疗效。结果:观察组治疗有效率为95%,高于对照组的75%,不良反应发生率为5%,低于对照组的20%,P<0.05。结论:雾化吸入重组人干扰素α1b治疗小儿急性毛细支气管炎的疗效显著,安全性高,值得推广。
Objective: To analyze the safety and efficacy of inhaled recombinant human interferon α1b in the treatment of acute bronchiolitis in children. Methods: A total of 40 children with acute bronchiolitis admitted to our hospital from January 2015 to January 2016 were randomly selected and divided into two groups. The patients in the control group were given conventional symptomatic treatment. On the basis of the control group, the observation group Inhalation of recombinant human interferon α1b inhalation treatment, the clinical efficacy of two groups were compared. Results: The effective rate of the observation group was 95%, higher than 75% of the control group, the incidence of adverse reactions was 5%, lower than 20% of the control group, P <0.05. Conclusion: Inhalation of recombinant human interferon α1b for the treatment of children with acute bronchiolitis has significant curative effect, high safety and is worth popularizing.